why choose us

First received: September 19, 2022

Clinical Trial: Ritlecitinib for Cicatricial Alopecia

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Cicatricial Alopecia

Study Type: INTERVENTIONAL


Official Title: A Pilot Study to Assess Safety and Biomarker Responses of Ritlecitinib (JAK3/TEC Inhibitor) in Cicatricial Alopecia

Brief Summary: Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed.CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair.Despite being a long-term condition, that often has significant impact on patients' well-being, available effective…

Read more